Narcaricin Mite (Benzbromarone)

Benzbromarone, the active ingredient in Narcaricin Mite, is a uricosuric agent presented as an oral tablet for oral use. It treats gout, hyperuricemia and related conditions in adult patients. GNH USA supplies Narcaricin Mite as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Narcaricin Mite, a uricosuric agent, is employed in the management of disorders associated with elevated uric acid levels. - Gout: reduces the frequency of acute attacks by lowering serum uric acid. - Hyperuricemia: maintains uric acid concentrations within target range to prevent disease progression. - Uric acid nephrolithiasis: facilitates dissolution and prevents formation of uric acid kidney stones.

Adverse reactions may occur with benzbromarone therapy.

Common Side Effects: - Gastrointestinal upset: nausea, dyspepsia, or abdominal discomfort. - Skin reactions: mild rash or pruritus. - Headache: transient episodes of mild to moderate intensity. - Dizziness: occasional light‑headedness. - Elevated liver enzymes: mild, transient increases in hepatic transaminases.

Serious or Rare Side Effects: - Severe hepatic injury: hepatitis or liver failure requiring monitoring. - Blood dyscrasias: agranulocytosis, leukopenia, or thrombocytopenia. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Acute renal failure: especially in patients with pre‑existing renal impairment. - Severe hypersensitivity reactions: anaphylaxis or serum sickness‑like syndrome.

Before initiating therapy, consider the following precautions. - Renal impairment: adjust use and monitor renal function regularly. - Hepatic dysfunction: avoid in patients with active liver disease and monitor liver enzymes. - Gout flare risk: prophylactic anti‑inflammatory therapy may be needed during initiation. - Drug interactions: review concomitant medications for potential interactions. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Benzbromarone may interact with several medicines; categorize as follows.

Major Interactions (Avoid): - Azathioprine: increased risk of bone‑marrow suppression. - Other uricosurics (e.g., probenecid): additive effect on uric acid excretion, raising toxicity risk. - Strong CYP2C9 inhibitors (e.g., fluconazole): elevate benzbromarone plasma levels.

Moderate Interactions (Monitor Closely): - NSAIDs: may affect renal clearance of uric acid. - Diuretics (thiazides): can reduce uricosuric efficacy. - ACE inhibitors or ARBs: monitor blood pressure and renal function. - Anticoagulants: potential alteration of INR, require periodic testing. - Allopurinol: combined urate‑lowering effect may necessitate dose adjustment.